Chol-DsiSTAT3 polyplexes suppress higher levels of total Stat3 protein [42% vs. 29%] (Figure 4C) and subsequent 4T1 tumor growth [rate-based T/C ratio of 8.6% vs. 11.5%] than Chol-siSTAT3 polyplexes after repeated IV administration every other day over 6 days (Figure 4A) at equimolar doses that saturate primary 4T1 breast tumors [2.0 mg Chol-siSTAT3/kg and 2.5 Chol-DsiSTAT3 mg/kg] (Figure 3A), and (iii). This evidence concerns the gene STAT3 and neoplasm.